Literature DB >> 16151877

Size matters -- patient organisations exaggerate prevalence numbers.

Anders Ternhag1, Tommi Asikainen, Johan Giesecke.   

Abstract

Patient organisations serve their members with information and support concerning a specific disease. In many cases they also contribute to research funding and lobby to improve the situation for their members. The larger group of patients an organisation claims to represent, the bigger their potential influence. Our hypothesis is that patient organisations exaggerate the number of persons affected with a specific disease. Prevalence figures from patient organisations in Sweden were collected via their own web sites. About 93 patient organisations were identified, 29 of which presented the estimates of disease occurrence used in this study. We calculated the probability for a person to have at least one disease and the proportion of the population not having any of the diseases listed. About 60% of the Swedish population have at least one disease covered by our sample of patient organisations. Nine tenths (87%) of the population would be ill if one assumes that an individual could only have one disease. Our rough estimates suggest that patient organisations exaggerate the number of ill persons. To render other messages on their agenda more trustworthy, we propose that some patient organisations moderate their prevalence and/or incidence figures.

Entities:  

Mesh:

Year:  2005        PMID: 16151877     DOI: 10.1007/s10654-005-0705-8

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  2 in total

1.  Patient organisations and the reimbursement process for medicines: an exploratory study in eight European countries.

Authors:  Janneke Noordman; Liset van Dijk; Roland Friele
Journal:  BMC Health Serv Res       Date:  2010-02-22       Impact factor: 2.655

2.  Advertising and disclosure of funding on patient organisation websites: a cross-sectional survey.

Authors:  Douglas E Ball; Klara Tisocki; Andrew Herxheimer
Journal:  BMC Public Health       Date:  2006-08-03       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.